H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $102 and keeps a Buy rating on the shares. The company’s 2026 is a pivotal year for volixibat as clinical evaluation progresses in two chronic immune-mediated cholestatic liver diseases, the analyst tells investors in a research note. The firm says colixibat could launch as early as the first half of 2027.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $101 from $94 at Evercore ISI
- Mirum Pharmaceuticals price target raised to $95 from $81 at Baird
- Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright
- Mirum price target raised at Baird after preliminary results
- Mirum Pharmaceuticals price target raised to $95 from $88 at Baird